Latest Tax Refunds News

Pilot Energy has locked in a $5.9 million debt facility tied to PRRT refunds, easing upfront funding pressures for decommissioning the Cliff Head oil field through 2027.

Hazer Group has received a $4.58 million R&D tax incentive refund for FY25, reinforcing its financial position as it advances its methane pyrolysis technology towards commercialisation.

Arovella Therapeutics has received a $3.21 million R&D tax incentive refund, bolstering its financial position as it prepares to initiate first-in-human trials for its lead cell therapy, ALA-101.

Control Bionics Limited reported a 14.8% revenue increase to $6.14 million for FY2025 but also a 3.3% rise in net loss to $6.11 million, while pursuing a $2 million rights issue and expanding its investment portfolio.

Aurora Labs reported a 34% increase in loss after tax to $3.75 million for FY2025, alongside a 327% surge in revenue driven by defence contracts and 3D printing services. The company is progressing its micro gas turbine propulsion systems and pursuing aerospace certification to expand its market footprint.

Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.

HPP has agreed to acquire Red Earth Energy Storage in a $40 million merger, aiming to relist on the ASX by early 2026 and capitalize on Australia’s growing battery storage market.

Starpharma has received a $3.7 million R&D Tax Incentive refund for the 2025 financial year, reinforcing its commitment to advancing dendrimer technology and biotechnology innovation in Australia.

Global Health Limited reported a reduced net loss for FY2025, driven by growing subscription revenue and strategic AI integration as it transitions to a SaaS platform.

Tabcorp Holdings delivered a robust FY25 performance, with revenue and earnings surging thanks to a new Victorian wagering licence and disciplined cost management. The company’s strategic shift towards omnichannel offerings underpins its optimistic outlook for FY26.

Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.

Health and Plant Protein Group Limited (HPP) reported a reduced net loss of $528,000 for FY2025, following the receipt of final proceeds from its US divestment. The Board signals plans to return capital and pursue new corporate opportunities.